갱년기 안면 홍조 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the menopausal hot flashes therapeutics market size is projected to be USD 7.62 billion in 2025, USD 8.12 billion in 2026, and reach USD 10.34 billion by 2031, growing at a CAGR of 4.95% from 2026 to 2031.

This report is Segmented by Treatment Type (Hormonal Treatment [Estrogen, and More], and Non-Hormonal Treatment [SSRIs, and More]), Route of Administration (Oral, and More), Distribution Channel (Hospital Pharmacies, and More), Menopausal Stage (Perimenopause and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Menopausal Hot Flashes Market Trends and Insights

Rise in Post-Menopausal Female Population Base

Longer life expectancy is lengthening the post-menopausal window, generating sustained prescription need. Japan expects its 65+ female cohort to expand by 1.8 million between 2024-2030, while the United States projects more than 58 million women aged 50+ by 2030. These population shifts persuaded Medicare Part D to list fezolinetant in January 2025, albeit with prior-authorization hurdles that reference prior HRT failure. Similar demographic curves in South Korea and Italy motivate payer reviews that gradually widen reimbursement for both transdermal HRT and NK-3 antagonists.

Growing Pharmaceutical Investment in Women's-Health Portfolios

Global venture funding for women's health touched USD 3.1 billion in 2024, a 42% jump year over year. Bayer is spending EUR 150 million on additional Climara patch capacity in Finland, targeting 25% output growth by 2027. Organon disclosed USD 680 million menopause-related revenue in 2024, 18% of total sales, and guided to double-digit expansion for 2025. ARPA-H's newly funded projects include AI-driven symptom-tracking and novel NK-3 delivery systems, potentially trimming development cycles by up to two years.

Long-Term Hepatic Safety Concerns for NK-3 Antagonists

The FDA recorded three acute liver-injury cases among roughly 2,400 fezolinetant users, prompting a boxed warning that now mandates serial liver tests valued at USD 150-200 per patient. Astellas noted a 22% sequential prescription decline after the warning, especially in Medicare Advantage plans tightening prior authorization. The EMA is midway through a parallel safety review due in Q2 2026, and potential restrictions could echo across Europe.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid Approvals of Neurokinin-3 Receptor Antagonists
2. Employer Adoption of Menopause Benefits Platforms
3. Limited Reimbursement Outside OECD Markets

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Hormonal therapy controlled 62.55% of menopausal hot flashes therapeutics market share in 2025, anchored by broad familiarity and strong efficacy data. Non-hormonal agents, primarily NK-3 antagonists, selective serotonin reuptake inhibitors (SSRIs) and gabapentinoids, are poised for a 7.25% CAGR, benefiting estrogen-contraindicated segments and oncology survivors. The menopausal hot flashes therapeutics market size for non-hormonal products is projected to expand faster than HRT as payers increasingly reimburse fezolinetant following Medicare Part D listing. Progesterone monotherapy is emerging with supportive evidence from a 2024 Cochrane review, while herbal supplements remain marginal due to inconsistent potency and weak clinical validation.

Price erosion in legacy HRT is inevitable as biosimilar estradiol patches proliferate across Europe and India. FDA approval of estetrol-drospirenone, a fetal estrogen with lower clotting propensity, may slow attrition in the hormonal segment, yet oncology survivors and high-risk cardiovascular patients will likely bypass estrogen entirely, reinforcing non-hormonal momentum. Real-world data from 1.2 million U.S. charts indicate that NK-3 antagonist usage skews toward women with absolute HRT contraindications, suggesting additive rather than cannibalistic demand.

Oral therapies held 57.53% of 2025 volume, favored for lower list prices and prescribing inertia. Transdermal gels, sprays and patches are on a 7.75% CAGR trajectory through 2031, capitalizing on lower venous-thromboembolism risk and the convenience of dose titration. A meta-analysis of 14 cohort studies found a 2.1-fold reduction in VTE incidence for patches versus tablets. Microneedle and iontophoretic delivery systems trialed in 2024 achieved therapeutic estradiol levels within two hours without skin irritation, hinting at next-generation adherence solutions.

While transdermal patches dominate non-oral formulations, dissolving microneedle arrays could disrupt share by offering painless, discreet applications ideal for tropical climates where patches detach with sweat. Oral estetrol may partly offset transdermal gains in price-sensitive markets, but cold-chain-independent microneedle systems are likely to lift transdermal penetration across APAC and Africa as logistics improve.

Complete Report Scope:

• By Treatment Type
  • Hormonal Treatment
    • Estrogen
    • Progesterone
    • Estrogen-Progesterone Combination
  • Non-Hormonal Treatment
    • NK-3 Receptor Antagonists
    • SSRIs
    • SNRIs
    • Gabapentinoids
    • Herbal & Dietary Supplements
• By Route of Administration
  • Oral
  • Transdermal Patch
  • Transdermal Gel/Spray
  • Parenteral (Injectable)
  • Topical (Vaginal/Derma)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Menopausal Stage
  • Perimenopause
  • Early Post-Menopause (<5 yrs)
  • Late Post-Menopause (>5 yrs)
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America maintained 42.23% of 2025 revenue and will grow at 4.2% CAGR to 2031, amplified by Medicare Part D listing of fezolinetant and a robust network of specialty clinics. Canadian provinces adopted favorable reimbursement in late 2024, while Mexico's private sector imports transdermal patches from the United States to compensate for limited IMSS offerings. Corporate menopause programs are most mature here, cutting median therapy-initiation times to one month. FDA guidance released in 2024 that lowers trial burdens for symptomatic relief drugs should further energize pipeline velocity.

Asia-Pacific is projected to register a 7.42% CAGR-the fastest globally-as regulatory pathways converge and aging accelerates. Japan's 65+ female share rose to 28.9% in 2024, driving sustained patch usage. China's NMPA fast-tracked estradiol-progesterone combinations in 2025 and is reviewing elinzanetant under priority status, but cultural delay persists: fewer than 2% of symptomatic women seek prescription care. India's tele-medicine surge, headlined by Veera Health, shows rural engagement when language-localized virtual care is offered. South Korea's insurance co-pay reset to 30% for patches in 2024 caused a 47% utilization jump.

Europe's centralized EMA approvals streamline launches; fezolinetant gained clearance in November 2024, and biosimilar patches slashed prices up to 35% in Germany and France. NHS England's pilot cut wait times to under five days, spurring 31% higher HRT initiation rates. Italy and Spain remain fully out-of-pocket markets for vasomotor indications, hamstringing adoption. Eastern Europe lags in awareness, although EU cohesion funds back education drives in Poland and Romania.

Middle East & Africa expands from a small base. Saudi Arabia's insurance package now mandates HRT coverage, and the SFDA fast-tracked fezolinetant in January 2025. In the UAE, expatriate women commonly pay cash because private plans exclude menopause care, while South Africa's reimbursement ceiling of ZAR 120 limits branded product reach. Telehealth pilots in Kenya and Nigeria demonstrate early promise in circumventing cultural resistance and provider shortages. South America is dominated by Brazil, where SUS funds generic estradiol tablets yet omits patches and NK-3 antagonists. Cold-chain limitations complicate patch logistics across Amazonian states, and most advanced therapies are confined to private-pay urban markets.

1. Abbvie
2. Astellas Pharma
3. Bayer
4. Besins Healthcare
5. Cipla
6. Eisai
7. Endoceutics Inc.
8. Ferring Pharmaceuticals
9. Fervent Pharmaceuticals
10. Hisamitsu Pharmaceutical Co. (Noven)
11. KaNDy Therapeutics
12. Knight Therapeutics Inc.
13. Lupin
14. Mithra Pharmaceuticals
15. Novo Nordisk
16. Organon
17. Pfizer
18. Sun Pharma Ind. Ltd.
19. Teva Pharmaceutical Ind.
20. Theramex
21. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rise in post-menopausal female population base
  • 4.2.2 Growing pharmaceutical investment in women's health portfolios
  • 4.2.3 Rapid approvals of neurokinin-3 receptor antagonists
  • 4.2.4 Employer adoption of menopause benefits platforms
  • 4.2.5 AI-enabled precision dosing & companion diagnostics
  • 4.2.6 Expansion of tele-menopause virtual clinics in underserved regions
• 4.3 Market Restraints
  • 4.3.1 Long-term hepatic safety concerns for NK-3 antagonists
  • 4.3.2 Limited reimbursement outside OECD markets
  • 4.3.3 Cultural stigma suppressing care-seeking in Asia & MENA
  • 4.3.4 Regulatory ambiguity for botanical OTC supplements
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Treatment Type
  • 5.1.1 Hormonal Treatment
    • 5.1.1.1 Estrogen
    • 5.1.1.2 Progesterone
    • 5.1.1.3 Estrogen-Progesterone Combination
  • 5.1.2 Non-Hormonal Treatment
    • 5.1.2.1 NK-3 Receptor Antagonists
    • 5.1.2.2 SSRIs
    • 5.1.2.3 SNRIs
    • 5.1.2.4 Gabapentinoids
    • 5.1.2.5 Herbal & Dietary Supplements
• 5.2 By Route of Administration
  • 5.2.1 Oral
  • 5.2.2 Transdermal Patch
  • 5.2.3 Transdermal Gel/Spray
  • 5.2.4 Parenteral (Injectable)
  • 5.2.5 Topical (Vaginal/Derma)
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Online Pharmacies
• 5.4 By Menopausal Stage
  • 5.4.1 Perimenopause
  • 5.4.2 Early Post-Menopause (?5 yrs)
  • 5.4.3 Late Post-Menopause (>5 yrs)
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AbbVie Inc.
  • 6.3.2 Astellas Pharma Inc.
  • 6.3.3 Bayer AG
  • 6.3.4 Besins Healthcare
  • 6.3.5 Cipla Ltd.
  • 6.3.6 Eisai Co. Ltd.
  • 6.3.7 Endoceutics Inc.
  • 6.3.8 Ferring Pharmaceuticals
  • 6.3.9 Fervent Pharmaceuticals
  • 6.3.10 Hisamitsu Pharmaceutical Co. (Noven)
  • 6.3.11 KaNDy Therapeutics
  • 6.3.12 Knight Therapeutics Inc.
  • 6.3.13 Lupin Ltd.
  • 6.3.14 Mithra Pharmaceuticals
  • 6.3.15 Novo Nordisk A/S
  • 6.3.16 Organon & Co.
  • 6.3.17 Pfizer Inc.
  • 6.3.18 Sun Pharma Ind. Ltd.
  • 6.3.19 Teva Pharmaceutical Ind.
  • 6.3.20 Theramex
  • 6.3.21 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment